If you missed the cannaBUS, jump on the psilocybin train
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Now is the time to buy these 10 psychedelic stocks.
When the cannabis company GW Pharmaceuticals sold for billions earlier this year, those who didn’t invest were left with major regret. If you missed out on cannabis, now is your chance to be an early investor in the shroom boom as psychedelic companies begin to follow a similar pathway. These 10 companies are worth the buy according to Maxim Group’s latest analysis.
Cybin aims to treat COVID-related distress in frontline healthcare workers using new psychotherapy model
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
A new University of Washington study co-sponsored by Cybin aims to treat COVID-related depression, anxiety, burnout and post-traumatic stress in frontline healthcare workers using psychedelic-assisted psychotherapy. The study will test Cybin’s new transdiagnostic psychotherapy model called EMBARK, which is “aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics”. Cybin CEO Doug Drysdale says he considers it an honour to support the frontline workers who made great sacrifices for the public throughout the pandemic.
Cybin’s psychedelic drug formualtion will target Alcohol Use Disorder
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003
Cybin announced that its proprietary new chemical entity (NCE), CYB003, will target Alcohol Use Disorder in response to increased alcohol use during the pandemic. CEO Doug Drysdale is optimistic that CYB003 will provide “a durable respite from alcohol dependence and the potential to overcome this often-crippling disease”.